Ophthalmic composition for the treatment of ocular infection
AssigneeCooperVision International Holding Company, LP
InventorErwin C. Si
Life of this patent
Estimating the term…
Abstract
An ophthalmic composition for administration to an eye of a patient for the treatment of an ocular infection. The ophthalmic composition contains an ε-polylysine (εPL) in an amount effective to treat or control or prevent the ocular infection.
Claims18
An ophthalmic composition for use in the treatment of an ocular infection when the ophthalmic composition is administered to an eye of a patient, or the prophylaxis of an ocular infection when the ophthalmic composition is administered to an eye of a patient before or after the introduction of an inoculum of an ocular pathogen, said composition consisting essentially of a pharmaceutically-acceptable carrier, an amount of ε-polylysine (εPL) effective for said treatment, and optionally at least one non-active agent, wherein the ophthalmic composition is provided as a liquid in an eye-drop dispensing bottle or vial, or as a unit dose ocular insert for placement in a cul de sac of the patient's eye, wherein the composition comprises no preservative agent in addition to the ε-polylysine (εPL).
A method for the treatment of an ocular infection of a patient, said method comprising topically administering of an ophthalmic composition consisting essentially of a pharmaceutically-acceptable carrier, an effective amount of ε-polylysine (εPL), and optionally at least one non-active agent, to the patient's eye, wherein the ophthalmic composition is administered as a liquid from an eye-drop dispensing bottle or vial, or as a unit dose ocular insert placed in a cul de sac of the patient's eye, and wherein the composition comprises no preservative agent in addition to the ε-polylysine (εPL), or a method for the prophylaxis of an ocular infection of a patient, said method comprising topically administering of an ophthalmic composition consisting essentially of a pharmaceutically-acceptable carrier, an effective amount of ε-polylysine (εPL), and optionally at least one non-active agent, to the patient's eye before or after the introduction of an inoculum of an ocular pathogen, wherein the ophthalmic composition is administered as a liquid from an eye-drop dispensing bottle or vial, or as a unit dose ocular insert placed in a cul de sac of the patient's eye, and wherein the composition comprises no preservative agent in addition to the ε-polylysine (εPL).
Dependencies are inferred from the claim text.